
SyntheticGestalt KK (headquarters: Minato-ku, Tokyo; CEO: Koki Shimada; hereinafter "our company") is pleased to announce that Daisuke Morohashi, Head of AI Business, presented as the main speaker at the FY2026 "Kyoto Startup Overseas Expansion Support Project" briefing session, co-hosted by Kyoto City and Plug and Play Japan on Thursday, May 14, 2026.
Invited as a "leading case of successful overseas expansion" by Kyoto City and Plug and Play
Our company was invited as a leading example of a startup that has achieved success in overseas expansion within the overseas expansion support project jointly promoted by Kyoto City and the global accelerator Plug and Play Japan. In a dialogue with Seiji Iwasaki (Senior Manager, Head of Kyoto, Plug and Play Japan), Morohashi shared practical insights into business development in the global market.
SyntheticGestalt's overseas expansion track record — "Creating the Wow of Drug Discovery with AI" globally
Founded in London in 2018 and now headquartered in Tokyo, SyntheticGestalt is a molecular AI technology startup. With the vision of "Creating the Wow of Drug Discovery with AI," the company leverages SG4D10B — the world's largest 4D molecular foundation AI model — to deploy AI technology across drug discovery, agrochemicals, chemicals, and food science.
The presentation covered the company's global expansion journey across three phases:
Phase 1 (2018–2023): Foundation
• Founded in London, relocated headquarters to Tokyo
• Closed Series A at $14M (UK/Japan VCs)
• Presented at NVIDIA GTC 2024 (San Jose, USA)
• Selected for Forbes "50 Notable AI Startups"
• Selected for J-Startup (Ministry of Economy, Trade and Industry)
Phase 2 (2024–2026): Going on the offensive — maximising in-person encounters
• Exhibited at Discovery on Target (Boston): 35 contacts, 15 leads
• Participated in JETRO BIO International Convention (Boston)
• Selected for AWS Generative AI Accelerator (Seattle) from among generative AI startups worldwide
• Participated in Link-J UNIKORN × Bio Europe
• Joined Mayo Clinic cohort via JETRO J-StarX
• Consecutively selected for GENIAC Phases 2 and 3
Phase 3 (2026–): Full-scale overseas operations
• Series B $20M round in progress (US VC lead anticipated)
• US office establishment in preparation (Boston/SF under consideration)
• Accelerating overseas deployment of 3 products (Zao/Hakuba/Koya)
Key takeaways shared: "Textbook vs Reality"
• Relationships matter even more than in Japan — business is nearly impossible without connections
• Mass email approaches have extremely low conversion rates; the most effective approach is post-presentation conversations and networking receptions
• A 20% plan executed immediately beats a 100% plan never launched
• English materials require "reconstruction," not translation — headline first, KPIs within the first 3 seconds
• Opportunities arrive unexpectedly and demand immediate decisions
